Main Article Content


The classification of rheumatic diseases is still challenging due to several reasons. First, those diseases have several differential clinical features, which giving overlap symptoms. Second, the etiopathogenesis of those diseases remains elusive.
Diagnosis of overlap syndrome is made when there are more than one well-defined connective tissue diseases in one patient, which may develop simultaneously or sequentially.1,2 The prevalence of overlap syndrome among autoimmune diseases is
25%.2 The term sclerodermatomyositis or scleromyositisis is used to describe an overlap syndrome in patients with scleroderma and dermatomyositis/polymyositis (DM/PM).2,3,4 Sclerodermatomyositis usually affects adults, and it is rarely found in children.4 The clinical features of this syndrome are myalgia or myositis, arthralgia, scleroderma-like skin changes, Raynaud’s phenomenon (RP),2,3 interstitial lung disease, calcinosis,3 mask-like facies, dysphagia or esophageal dysmotility,4 as well as the presence of specific antibody Pm/Scl.2 Skin manifestations as the part of dermatomyositis include periorbital erythema and Gottron’s papules.3 We report this case due to its very rare occurrence. According to medical records in the Department of Dermatology as well as Rheumatology at Hasan Sadikin Hospital, Bandung, this is the first case recorded in the last 10 years.

Article Details

How to Cite
Febyani, M., D, H. P., Hamijoyo, L., Sutedja, E., & Suwarsa, O. (2018). Sclerodermatomyositis. Indonesian Journal of Rheumatology, 3(1).


  1. Hoffman RW. Overlap syndromes, mixed connective tissue disease, and undifferentiated connective tissue disease. In: Tsokos GC, Gordon C, Smolen JS, editors. Systemic lupus erythematosus a companion to rheumatology. Philadelphia: Elsevier; 2007. p. 429-37.
  2. Jury EC, D’Cruz D, Morrow WJ. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. J ClinPathol 2001;54:340-7.
  3. Jablonska S, Blaszcyk M. Scleromyositis: a scleroderma/polymyositis overlap syndrome. ClinRheumatol 1998;17:465-7.
  4. Marcus M, Ilyas M, Tolaymat A. Childhood scleromyositis with a negative PM/Scl antibody. Joint Bone Spine 2010;77:73-5.
  5. Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am AcadDermatol 2008;59:99-112.
  6. James WD, Berger TG, Elston DM, editors. Andrews’ diseases of the skin clinical dermatology. 10th ed. Canada: Elsevier; 2006. p. 166-77.
  7. Sontheimer RD, Costner MI. Dermatomyositis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. 7thed. New York: McGraw-Hill; 2008.p. 1536-53.
  8. Sontheimer RD. The management of dermatomyositis: current treatment options. Expert OpinPharmacother 2004;5:1083-99.
  9. Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number; characteristics, and classifi cation of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am AcadDermatol 2007;57:937-43.
  10. Nagaraju K, Lundberg IE. Infl ammatory diseases of muscle and other myopathies. In: Firestein GS, Budd RC, Harris ED, Mcinnes IB, Ruddy S, Sergent JS, editors. Kelley’s textbook of rheumatology. 8th ed. Philadelphia: Elsevier; 2009. p.1353-78.
  11. Goodfi eld MJD, Jones SK, Veale DJ. Connective tissue disease. In: Burns T, Breathnach S, Cox N, Griffi ths C, editors. Rook’s textbook of dermatology. 7th ed. Massachusetts: Blackwell Science; 2004. p. 56,91-116.
  12. Hall JAM. Dermatomyositis-scleroderma overlap syndrome presenting as autoimmune haemolyticanaemia. Rheumatology 2002;41:956-8.
  13. Jorizzo JL. Dermatomyositis. In: Bolognia JL, Jorrizo JL, Rapini RP, editors. Dermatology. New York: Mosby; 2003. p. 615-22.
  14. Hoffman RW. Mixed connective tissue disease and overlap syndromes. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 975-87.
  15. Ramos GR, Diaz VG, Tovar MG, Luna A, Diaz EA, Esparza R. A dermatomyositis and scleroderma overlap syndrome with remarkable high titer of anti-exosome antibodies. Reumatismo 2008:60:296-300.
  16. Bennet RM. Overlap syndromes. In: Firestein GS, Budd RC, Harris ED, Mcinnes IB, Ruddy S, Sergent JS, editors. Kelley’s textbook of rheumatology. 8th ed. Philadelphia: Elsevier; 2009. p. 1381-97.
  17. Maddison PJ. Mixed connective tissue disease overlap syndromes. Bailliere’sClinRhematol 2004;14(1):111-24
  18. Denton CP, Black CM. Scleroderma (systemic sclerosis). In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill Incorporation; 2008. p. 1553-62.
  19. Seibold JR. Scleroderma and mixed connective tissue diseases. In: Ruddy S, Harris ED, Sledge C, editors. Kelley’s textbook of rheumatology. 6th ed. Massachusetts:W.B. Saunders Company; 2001. p. 1211-31.
  20. Falanga V. Systemic sclerosis (scleroderma). In: Bolognia JL, Jorrizo JL, Rapini RP, Editors. Dermatology. New York: Mosby-Year Book Incorporation; 2003. p. 625-631.
  21. Winfi eld H, Jawrosky C. Connective Tissue Disease. In: Elder D, Elenitsas R, Johnson BL, Murphy GF, editors. Lever’s histopathology of the skin. 10th ed. Philadelphia: Lippincott-Raven; 2009. p. 293-296.
  22. Weedon D. Weedon’s skin pathology. 3rd ed. Canada:Elsevier; 2009. p.64-66,304-10.
  23. Desai SP, Isa-Pratt S. Rheumatology. In: Clinician’s guide to laboratory medicine a practical approach. Ohio: Lexi-comp Incorporation; 2000. p.587-624.
  24. Nakamura RM. Clinical and laboratory evaluation of systemic rheumatic diseases. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: W.B. Saunders Company; 1996. p. 1013-23.
  25. Sunkureddi P, Oghalai TU, Jarvis JL, Karnath BM. Signs of dermatomyositis.Hospital Physic 2005;7:41-4.
  26. Fiorentino DF, Callen JP. Dermatomyositis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, editors. Evidence-base dermatology. 2nd ed. Victoria: Blackwell Publishings; 2008. p. 559-70.
  27. Wolverton SE. Corticosteroid and the integument. In: Lin AN, Paget SA, editors. Principles of corticosteroid therapy. New York: Arnold; 2002. p.166-7.
  28. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang TJ. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthitis Research Ther 2010;12:1-7.
  29. Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. In: Kasper LD, Braunwald E, Fauci AS, Hauser SL, Longo DL, editors. Harrison’s principles of internal medicine. 16th ed. New York: McGrawHill; 2005. p. 2540-5.